BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 30219191)

  • 1. PET in the Diagnostic Management of Soft Tissue Sarcomas of Musculoskeletal Origin.
    Katal S; Gholamrezanezhad A; Kessler M; Olyaei M; Jadvar H
    PET Clin; 2018 Oct; 13(4):609-621. PubMed ID: 30219191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/Computed Tomography and Precision Medicine: Musculoskeletal Sarcoma.
    Kandathil A; Subramaniam RM
    PET Clin; 2017 Oct; 12(4):475-488. PubMed ID: 28867117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional image in soft tissue sarcomas: An update of the indications of
    Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
    J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors.
    Peterson JJ
    Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular imaging of sarcomas with FDG PET.
    Mendoza H; Nosov A; Pandit-Taskar N
    Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron Emission Tomography/Computed Tomography Transformation of Oncology: Musculoskeletal Cancers.
    Broski SM
    PET Clin; 2024 Apr; 19(2):217-229. PubMed ID: 38184453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic value of
    Kassem TW; Abdelaziz O; Emad-Eldin S
    Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pediatric FDG PET/CT: Physiologic uptake, normal variants, and benign conditions [corrected].
    Bestic JM; Peterson JJ; Bancroft LW
    Radiographics; 2009; 29(5):1487-500. PubMed ID: 19755607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PET with
    Harrison DJ; Parisi MT; Khalatbari H; Shulkin BL
    PET Clin; 2020 Jul; 15(3):333-347. PubMed ID: 32498989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET for evaluating musculoskeletal tumors: a review.
    Aoki J; Endo K; Watanabe H; Shinozaki T; Yanagawa T; Ahmed AR; Takagishi K
    J Orthop Sci; 2003; 8(3):435-41. PubMed ID: 12768492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of [18-F]] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas.
    Schwarzbach MH; Dimitrakopoulou-Strauss A; Willeke F; Hinz U; Strauss LG; Zhang YM; Mechtersheimer G; Attigah N; Lehnert T; Herfarth C
    Ann Surg; 2000 Mar; 231(3):380-6. PubMed ID: 10714631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
    Jones DN; McCowage GB; Sostman HD; Brizel DM; Layfield L; Charles HC; Dewhirst MW; Prescott DM; Friedman HS; Harrelson JM; Scully SP; Coleman RE
    J Nucl Med; 1996 Sep; 37(9):1438-44. PubMed ID: 8790188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of
    Harrison DJ; Parisi MT; Shulkin BL
    Semin Nucl Med; 2017 May; 47(3):229-241. PubMed ID: 28417853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advantages of
    Németh Z; Boér K; Borbély K
    Pathol Oncol Res; 2019 Jan; 25(1):131-136. PubMed ID: 28994004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.